In February 2021, GSK announced that it will work with CureVac to jointly develop next-generation mRNA vaccines for COVID-19 with the potential to address multiple emerging variants. In addition, the company will support the manufacture of 100 million doses of CureVac’s first-generation COVID-19 vaccine candidate in 2021.
This new COVID-19 agreement builds on the existing relationship between GSK and CureVac. In July 2020, GSK announced a strategic collaboration to research, develop, manufacture and commercialize up to five mRNA-based vaccines and monoclonal antibodies.